Home > Insider Trading > Filing (0000899243-20-026193)

Filing Details

Accession Number:: 0000899243-20-026193
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-09-23 19:11:31
Reporting Period:: 2020-09-21

Accepted Time:: 2020-09-23 19:11:31
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1818794	Dyne Therapeutics Inc.	DYN	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1776851	Vida Ventures Ii, Llc	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No
1781930	Vida Ventures Ii-A, Llc	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No
1824569	Vv Manager Ii, Llc	40 Broad Street, Suite 201 Boston MA 02109	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-09-21	2,087,130	$0.00	2,087,130	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2020-09-21	792,995	$19.00	2,880,125	No	4	P	Indirect	See footnotes
Common Stock	Acquisiton	2020-09-21	57,916	$0.00	57,916	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-09-21	22,005	$19.00	79,921	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	P	Indirect	See footnotes
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2020-09-21	6,922,803	$0.00	2,087,130	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-09-21	192,102	$0.00	57,916	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The shares are held directly by Vida Ventures II, LLC ("Vida II"). VV Manager II, LLC ("VV Manager II") is the manager of Vida II. Arie Belldegrun, Fred Cohen, and Leonard Potter are the members of the management committee of VV Manager II (the "Management Committee") and Stefan Vitorovic, Arjun Goyal, Helen Kim, Rajul Jain, and Joshua Kazam are the members of the investment committee of VV Manager II (the "Investment Committee").
(Continued from Footnote 2) Each of the Management Committee, the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.
The shares are held directly by Vida Ventures II-A, LLC ("Vida II-A"). VV Manager II is the manager of Vida II-A. Each of the Management Committee ,the Investment Committee and the respective members thereof may be deemed to share voting and dispositive power over the shares held by Vida II-A. VV Manager II, the Management Committee, the Investment Committee and each member of each of the Management Committee and Investment Committee disclaims beneficial ownership over the securities held of record by Vida II-A and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interest therein.